AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 31816352
Drug: Orally disintegrating
RxNorm normalized name: Clozapine Orally Disintegrating Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally disintegrating tablets (ODTs) with water-soluble radiolabel (111Indium-diethylenetriaminepentaacetic acid) without water ingestion
Trial: 31816352
Drug: Orally disintegrating
RxNorm normalized name: Clozapine Orally Disintegrating Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally disintegrating tablets (ODTs) with water-soluble radiolabel (111Indium-diethylenetriaminepentaacetic acid) with water ingestion
Trial: 24425854
Drug: Daily irrigation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily irrigation with sterile saline solution during silicone hydrogel contact lens continuous wear.
Trial: 23218158
Drug: Adjunctive oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive oral ziprasidone
Trial: 8387071
Drug: Placebo (9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (9 mg/kg dextrose)
Trial: 30002707
Drug: Oral ibuprofen
RxNorm normalized name: ibuprofen Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ibuprofen (OI) 1200 mg/day
Trial: 18949179
Drug: captopril 50
RxNorm normalized name: captopril 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: captopril 50 mg/kg/day (in rats)
Trial: 11154142
Drug: Oral 17beta-estradiol
RxNorm normalized name: Estradiol-17beta
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral 17beta-estradiol (2 mg daily) for 8 weeks
Trial: 9329065
Drug: 2 capsules
RxNorm normalized name: Xymogen Berberine With Insea2 Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 capsules
Trial: 18822172
Drug: Trial chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trial chemotherapy and FLC removal haemodialysis
Trial: 18822172
Drug: Trial chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trial chemotherapy and standard high flux haemodialysis
Trial: 25903742
Drug: Nefopam (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefopam (160 mg in 200 ml at a rate of 4 ml/h)
Trial: 21357827
Drug: Dual therapy
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual therapy (telmisartan and ramipril)
Trial: 21357827
Drug: Angiotensin receptor
RxNorm normalized name: Angiotensin receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin receptor blocker (telmisartan)
Trial: 21205715
Drug: Inhaled fluticasone
RxNorm normalized name: fluticasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled fluticasone
Trial: 9509952
Drug: Body temperature
RxNorm normalized name: NITRIC OXIDE 400 mg in 500 mg TOPICAL CAPSULE [Bio NO Brain Care (Helps improve Brain blood flow and body temperature, Fermented Garlic powder)]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Body temperature (BT), erythrocyte sedimentation rate (ESR), and serum leukocyte concentration (L)
Trial: 7995154
Drug: Interferon alfa-n3
RxNorm normalized name: Interferon alfa-n3
DrugBank: Interferon alfa-n3 (DB00018)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alfa-n3 (500,000 IU, 0.1 ml) injected into each quadrant of the anal canal after surgical excision and fulguration
Trial: 7995154
Drug: Saline (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline (0.1 ml) injected into each quadrant of the anal canal after surgical excision and fulguration
Trial: 26165918
Drug: Tdap-IPV (low-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tdap-IPV (low-dose diphtheria, tetanus, acellular pertussis and inactivated polio vaccine)
Trial: 26165918
Drug: Tdap +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tdap + OPV (low-dose diphtheria, tetanus, acellular pertussis vaccine with oral polio vaccine)
Trial: 26165918
Drug: Low-dose diphtheria
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose diphtheria vaccines
Trial: 21709065
Drug: Ticagrelor with
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor with low-dose maintenance aspirin
Trial: 21709065
Drug: Clopidogrel with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel with low-dose maintenance aspirin
Trial: 18413218
Drug: Diabetic subjects
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diabetic subjects in the DCCT intensive treatment group (n=479)
Trial: 17243593
Drug: Adper Prompt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adper Prompt L-Pop (AP)
Trial: 19058889
Drug: G-Bond (GB)
RxNorm normalized name: GB-13
DrugBank: GB-13 (DB18387)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-Bond (GB)
Trial: 29205080
Drug: Normofractionated therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normofractionated therapy
Trial: 29205080
Drug: Hypofractionated therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypofractionated therapy
Trial: 15576836
Drug: 2.8 g
RxNorm normalized name: glycerin 2.8 GM per 2.7 ML Enema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.8 g of phosphatidylinositol (PI) with food
Trial: 15576836
Drug: 2.8 g
RxNorm normalized name: glycerin 2.8 GM per 2.7 ML Enema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.8 g and 5.6 g of phosphatidylinositol (PI)
Trial: 9538962
Drug: Intermittent very‐low‐calorie
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent very‐low‐calorie diet (VLCD) for 5 consecutive days during week 2, followed by intermittent VLCD therapy for 1 day/week for 15 weeks (1‐day) or for 5 consecutive days every 5 weeks (5‐day)
Trial: 9538962
Drug: Intermittent VLCD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent VLCD therapy for 5 consecutive days every 5 weeks (5‐day)
Trial: 9538962
Drug: Standard behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard behavioral therapy (SBT) group with a 1,500‐1,800 kcal/day diet throughout
Trial: 20569068
Drug: Higher-dose BoNTA
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Higher-dose BoNTA (200-240 U)
Trial: 20569068
Drug: Lower-dose BoNTA
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower-dose BoNTA (120-150 U)
Trial: 20569068
Drug: BoNTA (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BoNTA (both doses)
Trial: 15992393
Drug: Bright light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bright light therapy (10,000 lux, 1 h daily)
Trial: 9030391
Drug: 3TC and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3TC and zidovudine combination
Trial: 10195531
Drug: 0.025 mg
RxNorm normalized name: lisuride 0.025 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.025 mg intrathecal morphine
Trial: 1800872
Drug: 0.125 mg
RxNorm normalized name: digoxin 0.125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.125 mg intrathecal morphine
Trial: 1800872
Drug: 0 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg intrathecal morphine (control)
Trial: 30859976
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as Usual (TAU) arm
Trial: 30859976
Drug: PGx-guided care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PGx-guided care arm (incongruent to congruent medication change)
Trial: 7848120
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg of subcutaneous sumatriptan
Trial: 11875637
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g branch chain amino acids
Trial: 11875637
Drug: 30 g
RxNorm normalized name: Lancet Unilet 30 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 g branch chain amino acids
Trial: 11875637
Drug: 60 g
RxNorm normalized name: aspirin 60 Grains
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 g branch chain amino acids
Trial: 10793931
Drug: Whole cell
RxNorm normalized name: pertussis, whole cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole cell pertussis vaccine
Trial: 8330470
Drug: Torsemide (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Torsemide (10 mg orally and intravenously)
Trial: 24769306
Drug: Pioglitazone 45
RxNorm normalized name: pioglitazone 45 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone 45 mg daily for 8 weeks
Trial: 15306578
Drug: OAC treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OAC treatment (omeprazole, amoxicillin, and clarithromycin)
Trial: 2883683
Drug: Zotepine low
RxNorm normalized name: zotepine
DrugBank: Zotepine (DB09225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zotepine low dosage (168 mg +/- 15 mg/die)
Trial: 31046033
Drug: 1,000 mg
RxNorm normalized name: bran 1,000 mg ORAL WAFER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,000 mg of standardized Withania somnifera extract (WSE)
Trial: 27789517
Drug: Drug-eluting stents
RxNorm normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-eluting stents
Trial: 25353657
Drug: .12% chlorhexidine
RxNorm normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: .12% chlorhexidine spray
Trial: 9745813
Drug: Systemic antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic antibiotic therapy
Trial: 9333146
Drug: Cidofovir (0.3%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cidofovir (0.3% or 1%) gel applied once daily for 5 days
Trial: 9333146
Drug: Cidofovir (0.3%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cidofovir (0.3% or 1%) gel
Trial: 12235450
Drug: Mefloquine (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mefloquine (250 mg weekly)
Trial: 8469191
Drug: Doxycycline (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline (50 mg daily) and chloroquine (300 mg weekly)
Trial: 28166296
Drug: FDC Soli
RxNorm normalized name: DYE FDC BLUE #1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDC Soli 6 mg + TOCAS
Trial: 28166296
Drug: FDC Soli
RxNorm normalized name: DYE FDC BLUE #1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDC Soli 9 mg + TOCAS
Trial: 18274887
Drug: Long-term GBE
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term GBE (300 mg/daily) combined with sex therapy
Trial: 18274887
Drug: Sex therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sex therapy alone
Trial: 16627376
Drug: Acarbose, 100
RxNorm normalized name: Acarbose, 100 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acarbose, 100 mg three times a day
Trial: 25638303
Drug: Dronedarone 400
RxNorm normalized name: dronedarone 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dronedarone 400 mg twice daily (BID)
Trial: 24296323
Drug: Etamicastat 50
RxNorm normalized name: Etamicastat
DrugBank: Etamicastat (DB15288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etamicastat 50 mg
Trial: 24296323
Drug: Etamicastat 100
RxNorm normalized name: Etamicastat
DrugBank: Etamicastat (DB15288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etamicastat 100 mg
Trial: 24296323
Drug: Etamicastat 200
RxNorm normalized name: Etamicastat
DrugBank: Etamicastat (DB15288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etamicastat 200 mg
Trial: 16597501
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (control group, n=30)
Trial: 16597501
Drug: Carbamazepine monotherapy
RxNorm normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carbamazepine monotherapy (following open-label treatment)
Trial: 29515151
Drug: Rectal swab
RxNorm normalized name: witch hazel .5 mL RECTAL SWAB [Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal swab samples
Trial: 27832025
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg valacyclovir twice daily
Trial: 28319423
Drug: Silexan 160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silexan 160 mg/d
Trial: 28319423
Drug: Silexan 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silexan 80 mg/d
Trial: 15531007
Drug: Paroxetine 20
RxNorm normalized name: PARoxetine 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine 20 mg/d
Trial: 15167707
Drug: Interferon-alpha2 (IFN-alpha2)
RxNorm normalized name: Fibroblast interferon
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon-alpha2 (IFN-alpha2) treatment
Trial: 11259325
Drug: Oral nateglinide
RxNorm normalized name: Nateglinide
DrugBank: Nateglinide (DB00731)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral nateglinide (120 mg)
Trial: 11259325
Drug: Intravenous nateglinide
RxNorm normalized name: Nateglinide
DrugBank: Nateglinide (DB00731)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous nateglinide (60 mg)
Trial: 31654943
Drug: Subcutaneous implantable
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous implantable cardioverter defibrillator (S‐ICD)
Trial: 19562533
Drug: iv paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iv paracetamol 1 g preoperatively (Group I)
Trial: 19562533
Drug: iv paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iv paracetamol 1 g intraoperatively (Group II)
Trial: 17659757
Drug: Azathioprine with
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azathioprine with methylprednisolone (AZA) treatment for 24 months
Trial: 9595977
Drug: Interferon beta-1a
RxNorm normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon beta-1a (6 MIU, 30 microg) administered via single intramuscular injection
Trial: 9595977
Drug: Interferon beta-1a
RxNorm normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon beta-1a (6 MIU, 30 microg) administered in the placebo-controlled phase III clinical trial
Trial: 23237936
Drug: Furosemide (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide (0.3 mg/kg) combined with mannitol (1 g/kg)
Trial: 16687991
Drug: Placebo (during
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (during discontinuation phase)
Trial: 12453926
Drug: Morphine 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 0.15 mg kg(‐1)
Trial: 15504188
Drug: Midazolam 0.30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 0.30 mg kg(‐1)
Trial: 7707164
Drug: Short-acting ACE
RxNorm normalized name: Short-acting sulfonamides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-acting ACE inhibitors (captopril and quinapril) given twice a day
Trial: 7707164
Drug: Long-acting ACE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting ACE inhibitors (enalapril, lisinopril, benazepril, cilazapril) given once a day
Trial: 904549
Drug: 0.15 g
RxNorm normalized name: AZELAIC ACID 0.15 g in 1 g TOPICAL GEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.15 g phenformin/day
Trial: 25963481
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg pradigastat with a low-fat meal
Trial: 25963481
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg pradigastat with a high-fat meal
Trial: 25963481
Drug: Fasted or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasted or fed conditions (both 20 and 40 mg doses)
Trial: 21640879
Drug: Orthodontic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orthodontic treatment with fixed appliances (bands and brackets)
Trial: 20110014
Drug: Venlafaxine ER
RxNorm normalized name: Venlafaxine ER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine ER 37.5 mg tablets (study A)
Trial: 20110014
Drug: Venlafaxine ER
RxNorm normalized name: Venlafaxine ER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine ER 75 mg tablets (study B)
Trial: 16304557
Drug: alfuzosin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alfuzosin (10 or 15 mg) once daily for 3 months
Trial: 2576327
Drug: Theophylline and
RxNorm normalized name: theophylline and adrenergics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline and beta-adrenergic agonists combination
Trial: 1119820
Drug: 1.0% colchicine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0% colchicine in hydrophilic ointment applied once daily for 6 to 12 weeks
Trial: 31202270
Drug: Blended psychosocial
RxNorm normalized name: Io-Blend
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blended psychosocial support program based on Acceptance and Commitment Therapy
Trial: 26314902
Drug: Gabapentin 800
RxNorm normalized name: gabapentin 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin 800 mg (2 hours prior to induction)
Trial: 23351633
Drug: 180 g
RxNorm normalized name: GLYCERIN 9 mg in 180 g / PANTHENOL 7 mg in 180 g CUTANEOUS FILM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 180 g of farmed Atlantic salmon, twice per week for 4 weeks
Trial: 15259285
Drug: Isoflavone supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoflavone supplementation (two tablets of an extract of aglycone isoflavones from red clover for 6 months)
Trial: 11284785
Drug: 3 or
RxNorm normalized name: Cytra-3 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 or 5 MU IFN‐alpha daily for 1 month, followed by the same dose three times a week for 11 months
Trial: 26423649
Drug: Ongoing triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ongoing triple therapy (OT)
Trial: 26986803
Drug: Ritonavir-boosted PI
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ritonavir-boosted PI monotherapy (PI-mono)
Trial: 23297506
Drug: Oral levofloxacin
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral levofloxacin 0.2 g bid for 4‐6 weeks and oral Terazosin at 2 mg qd for 2 months
Trial: 18611339
Drug: Modified regime
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified regime with epinephrine (K=1 mg) and aminophylline (7 mg/kg)
Trial: 18611339
Drug: Modified regime
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified regime with epinephrine (K=2 mg) and aminophylline (7 mg/kg)
Trial: 18611339
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with standard epinephrine treatment (1 mg every 3 minutes if no effect)
Trial: 24606096
Drug: Growth Hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth Hormone (GH) treatment
Trial: 9280254
Drug: Resovist (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resovist (all doses)
Trial: 1952999
Drug: 30 U/m2/week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 U/m2/week growth hormone treatment
Trial: 1952999
Drug: 15 U/m2/week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 U/m2/week growth hormone treatment
Trial: 30755256
Drug: Topical Tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical Tranexamic Acid (tTXA)
Trial: 25053129
Drug: Vaccination with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccination with autologous DC loaded with tumor lysate/homogenate combined with preleukapheresis IFN-α (3 MU subcutaneous for 7 days)
Trial: 17355587
Drug: Intensive medication
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive medication management (MedMgt)
Trial: 17355587
Drug: Behavioral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral treatment (with or without medication)
Trial: 14998110
Drug: Community care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community care (CC)
Trial: 14749863
Drug: 2.5% arginine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5% arginine hydrochloride ointment
Trial: 11176663
Drug: Minocycline, 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minocycline, 200 mg/d for a median duration of 12 months
Trial: 9923586
Drug: Antihypertensive medication
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive medication (various classes including diuretics, beta blocking agents, calcium channel blockers, ACE inhibitors, hypotensives)
Trial: 9923586
Drug: ACE inhibitors
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitors and diuretics
Trial: 9923586
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (diuretic with beta blocking agent)
Trial: 11566623
Drug: Interleukin-2 therapy
RxNorm normalized name: Interleukin-2 aldesleukin
DrugBank: Aldesleukin (DB00041)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interleukin-2 therapy
Trial: 29943744
Drug: Oral Vitamin
RxNorm normalized name: vitamin A Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Vitamin D supplementation